Phillip Samayoa - Sep 16, 2022 Form 3 Insider Report for Generation Bio Co. (GBIO)

Role
CHIEF STRATEGY OFFICER
Signature
/s/ Benjamin Waters, Attorney-in-Fact
Stock symbol
GBIO
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
3
Date filed
9/20/2022, 04:05 PM
Next filing
Oct 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GBIO Common Stock 92.9K Sep 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 6.75K $4.59 Direct F1
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 21.4K $5.16 Direct F2
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 31.1K $5.16 Direct F3
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 22K $30.25 Direct F4
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 5.5K $29.38 Direct F5
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 30K $35.66 Direct F6
holding GBIO Stock Option (right to buy) Sep 16, 2022 Common Stock 58.7K $6.49 Direct F7
holding GBIO Restricted Stock Units Sep 16, 2022 Common Stock 24.8K Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option to purchase 36,007 shares was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter.
F2 The option to purchase 31,138 shares was granted on March 5, 2020. The shares underlying the option vest over four years, with 25% of the shares vested on March 5, 2021 and the remaining shares vesting in equal quarterly installments thereafter.
F3 The option to purchase 31,138 shares was granted on March 5, 2020. The shares underlying the option vest in full upon the date on which the Board of Directors of the Issuer determines that the Issuer has dosed the initial patient in its first clinical trial, provided that such event occurs on or before July 1, 2023.
F4 The option to purchase 22,000 shares was granted on January 22, 2021. The shares underlying the option vest over four years, with 25% of the shares vested on January 22, 2022 and the remaining shares vesting in equal quarterly installments thereafter.
F5 The option to purchase 5,500 shares was granted on April 1, 2021. The shares underlying the option vest over two years, with 25% of the shares vested on October 1, 2021 and the remaining shares vesting in equal quarterly installments thereafter.
F6 The option to purchase 30,000 shares was granted on May 3, 2021. The shares underlying the option vest over four years, with 25% of the shares vested on May 3, 2022 and the remaining shares vesting in equal quarterly installments thereafter.
F7 The option to purchase 58,706 shares was granted on January 21, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on January 21, 2023 and the remaining shares vesting in equal quarterly installments thereafter.
F8 The grant of 33,000 restricted stock units was made on January 21, 2022. The shares underlying the restricted stock units vest over two years, with 25% of the shares vested on July 15, 2022 and the remaining shares vesting in equal quarterly installments thereafter.
F9 Each restricted stock unit represents the right to receive one share of the company's common stock.